Phenotypes of responders to mandibular advancement device therapy in obstructive sleep apnea patients: A systematic review and meta-analysis.

Mandibular advancement device Meta-analysis Obstructive sleep apnea Phenotype Systematic review

Journal

Sleep medicine reviews
ISSN: 1532-2955
Titre abrégé: Sleep Med Rev
Pays: England
ID NLM: 9804678

Informations de publication

Date de publication:
02 2020
Historique:
received: 17 05 2019
revised: 23 10 2019
accepted: 25 10 2019
pubmed: 1 12 2019
medline: 9 2 2021
entrez: 1 12 2019
Statut: ppublish

Résumé

Mandibular advancement device (MAD) therapy is the most commonly used non-continuous positive airway pressure (CPAP) treatment for obstructive sleep apnea (OSA). Although OSA patients prefer MAD over CPAP, on average over one third have minimal or no major reduction in OSA severity with MAD therapy. Improved understanding of responder characteristics (or "phenotypes") to MAD may facilitate more efficient use of limited medical resources and optimize treatment efficacy. The aim of this review is to describe the baseline phenotypic characteristics of responders to MAD therapy in OSA patients. Pubmed, Web of Science, EMBASE, Scopus were searched for eligible studies published until Feb 2019. A total of 650 studies were identified. 41 studies were included in this review and meta-analysis. The quality of the studies was assessed using the risk of bias assessment tool for non-randomized studies (RoBANS). Based on meta-analysis, the responders to MAD therapy had certain clinical phenotypic characteristics: lower age (95% CI: -4.55 to -1.62, p < 0.00001), female (95% CI: 0.56 to 0.91, p = 0.006), lower body mass index (95% CI: -2.80 to -1.11, p < 0.00001), smaller neck circumference (95% CI: -1.57 to -0.52, p < 0.00001), lower apnea-hypopnea index (95% CI: -7.23 to -1.89, p < 0.00001), a retracted maxilla and mandible, a narrower airway and a shorter soft palate than non-responders. The above-mentioned phenotypic responder characteristics provides useful information for the clinician when considering prescribing MAD therapy for OSA patients.

Identifiants

pubmed: 31785583
pii: S1087-0792(19)30197-2
doi: 10.1016/j.smrv.2019.101229
pii:
doi:

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101229

Subventions

Organisme : CIHR
ID : 325899
Pays : Canada

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Hui Chen (H)

Department of Orthodontics, School and Hospital of Stomatology, Shandong University & Shandong Provincial Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Laboratory for Dental Materials and Oral Tissue Regeneration, China; Department of Periodontology, School and Hospital of Stomatology, Shandong University & Shandong Provincial Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Laboratory for Dental Materials and Oral Tissue Regeneration, China; Faculty of Dental Medicine, Université de Montréal, Montreal, Que, Canada. Electronic address: h2.chen@acta.nl.

Danny J Eckert (DJ)

Adelaide Institute for Sleep Health (AISH): A Flinders Centre of Research Excellence College of Medicine and Public Health, Flinders University, Australia.

Paul F van der Stelt (PF)

Academic Centre for Dentistry Amsterdam, University of Amsterdam and Vrije Universiteit, Amsterdam, the Netherlands.

Jing Guo (J)

Department of Orthodontics, School and Hospital of Stomatology, Shandong University & Shandong Provincial Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Laboratory for Dental Materials and Oral Tissue Regeneration, China.

Shaohua Ge (S)

Department of Periodontology, School and Hospital of Stomatology, Shandong University & Shandong Provincial Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Laboratory for Dental Materials and Oral Tissue Regeneration, China. Electronic address: shaohuage@sdu.edu.cn.

Elham Emami (E)

Faculty of Dentistry, McGill University, Montreal, Canada.

Fernanda R Almeida (FR)

Faculty of Dentistry, University of British Columbia, Vancouver, Canada.

Nelly T Huynh (NT)

Faculty of Dental Medicine, Université de Montréal, Montreal, Que, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH